New Treatments Developed in Open Innovation Program
July 3, 2013 Editor 0
The University of Cambridge website reported that Cambridge researchers are developing new therapies as part of a collaborative program with industry. Two revolutionary treatments which could alleviate pain in people with hypersensitivity to heat, and provide a new regenerative therapy with MS sufferers, are being developed by University of Cambridge researchers at Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus. The program gives University researchers access to the drug development expertise of GSK and other pharmaceutical companies, while giving industry access to Cambridge research and know-how, in order to accelerate the development of new medicines.
Click here to read the full article.
- Open Innovation and Business Model: A Brazilian Company Case Study
- How to benefit from open innovation? An empirical investigation of open innovation, external partnerships and firm capabilities in the automotive industry
- Using Open Innovation to combat Ebola
- Open Innovation in Sports
- The Value of Open Innovation for B2B Companies
- Open Innovation Lessons
Subscribe to our stories
- The Strategic Role of Design in Driving Digital Innovation June 10, 2021
- Correction to: Hybrid mosquitoes? Evidence from rural Tanzania on how local communities conceptualize and respond to modified mosquitoes as a tool for malaria control June 10, 2021
- BRIEF FOCUS: Optimal spacing for groundnuts in smallholder farming systems June 9, 2021
- COVID-19 pandemic: impacts on the achievements of Sustainable Development Goals in Africa June 9, 2021
- Explicit knowledge networks and their relationship with productivity in SMEs May 30, 2021